Advocacy

Support the Reauthorization of the Rare Pediatric Disease Priority Review Voucher Program

On December 1, 2025, the House of Representatives passed the Give Kids a Chance Act (H.R. 1262), legislation that includes the reauthorization of the Rare Pediatric Disease Priority Review Voucher (PRV) Program. The EveryLife Foundation is urging the rare community to contact your Senators to reauthorize this critical program by passing the Give Kids a Chance Act of 2025 (H.R. 1262/S.932).

​

Take Action Today: https://everylifefoundation.quorum.us/campaign/110385/

​

About the PRV Program
The PRV Program incentivizes pharmaceutical companies to develop rare pediatric disease treatments at no cost to taxpayers. Before a treatment is approved, the company can obtain a Rare Pediatric Designation from the FDA. To be eligible, the drug must be eligible for priority review, and it must be the first approval for the drug’s active ingredient.
 

After the FDA approves an eligible treatment, the company is issued a PRV that can be used to obtain priority review for a treatment that wouldn’t otherwise qualify. Priority review means the FDA generally reviews a treatment within 6 months rather than the standard 10-month period.
 

Alternatively, the PRV can be sold to another company, generating revenue for the seller. The revenue generated from selling a PRV is part of the incentive for companies to invest in developing treatments for rare pediatric conditions. Companies purchase PRVs to get treatments on the market faster than the typical 10-month review period.

​

Here is a link to a YouTube Video that explains more about the PRV Program: https://youtu.be/3HLX07JYlPk

Here is a link to the EveryLife Foundation's website with additional information: https://everylifefoundation.org/prv/#toggle-id-3